ARRIVENT BIOPHARMA INC (AVBP) Stock News

NASDAQ:AVBP - Nasdaq - US04272N1028 - Common Stock - Currency: USD

22.05 -0.67 (-2.95%)

After market: 22.05 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AVBP Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Benzinga - Mentions: CNC MOH BV MESO ...

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

17 days ago - By: ArriVent BioPharma, Inc.

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

17 days ago - By: ArriVent BioPharma, Inc.

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

26 days ago - By: ArriVent BioPharma, Inc.

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

a month ago - By: ArriVent BioPharma, Inc.

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

a year ago - By: BusinessInsider

News Image

AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024

a year ago - By: InvestorPlace

AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024

a year ago - By: BusinessInsider

News Image

AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024

2 months ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports First Quarter 2025 Financial Results

4 months ago - By: Benzinga

ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside

5 months ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports Full Year 2024 Financial Results

a year ago - By: InvestorPlace

AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024

6 months ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

8 months ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

8 months ago - By: MarketBeat - Mentions: UPB CGON JNJ

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

10 months ago - By: ArriVent BioPharma, Inc.

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

a year ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

a year ago - By: ArriVent BioPharma, Inc.

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

a year ago - By: ArriVent BioPharma, Inc.

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

a year ago - By: ArriVent BioPharma, Inc.

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

a year ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports First Quarter 2024 Financial Results

a year ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports First Quarter 2024 Financial Results

a year ago - By: ArriVent BioPharma, Inc.

ArriVent Appoints Kristine Peterson to its Board of Directors

a year ago - By: ArriVent BioPharma, Inc.

ArriVent Appoints Kristine Peterson to its Board of Directors

a year ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports Full Year 2023 Financial Results

1 years ago - By: Seeking Alpha - Mentions: GS C

ArriVent BioPharma upsizes proposed IPO to $150M from $100M (Pending:AVBP)

2 years ago - By: Seeking Alpha - Mentions: GS C

ArriVent, lung cancer drug developer, files for $100M IPO (Pending:AVBP)